Page last updated: 2024-08-02 18:43:27
wp1066
Description
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 11210478 |
| CHEMBL ID | 1923234 |
| SCHEMBL ID | 1315831 |
| SCHEMBL ID | 1315826 |
| MeSH ID | M0509983 |
Synonyms (32)
| Synonym |
|---|
| wp1066 , |
| SCHEMBL1315831 |
| SCHEMBL1315826 |
| wp-1066 |
| 857064-38-1 |
| (s,e)-3-(6-bromopyridin-2-yl)-2-cyano-n-(1-phenylethyl)acrylamide |
| AKOS016007983 |
| wp 1066 |
| BCP0726000087 |
| CHEMBL1923234 |
| wp1066/wp-1066 |
| 2-propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-n-((1s)-1-phenylethyl)-, (2e)- |
| unii-63v8aie65t |
| 63v8aie65t , |
| gtpl7972 |
| HY-15312 |
| MLS006010178 |
| smr004701286 |
| DTXSID50235007 |
| AC-28413 |
| mfcd12912450 |
| EX-A760 |
| SW219153-1 |
| wp1066stat inhibitor iii |
| DB12679 |
| bdbm50557738 |
| S2796 |
| Q27089227 |
| AS-19242 |
| CCG-268106 |
| stat3 inhibitor iii, wp1066 |
| A863463 |
Protein Targets (3)
Potency Measurements
Inhibition Measurements
Bioassays (20)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1709760 | Cytotoxicity against human HEK 293T cells assessed as cell growth inhibition at 50 uM measured after 48 hrs by MTT assay | 2021 | ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
ISSN: 1948-5875 | |
| AID632967 | Antitumor activity against human U266 cells after 24 to 72 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
ISSN: 1464-3391 | Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. |
| AID1768839 | Cytotoxicity against human HCCLM3 cells assessed as cell viability up to 50 uM measured upto 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 50ISSN: 1464-3405 | Pyrimidine-2,4-dione targets STAT3 signaling pathway to induce cytotoxicity in hepatocellular carcinoma cells. |
| AID1768838 | Cytotoxicity against human HepG2 cells assessed as cell viability up to 50 uM measured upto 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry letters, 10-15, Volume: 50ISSN: 1464-3405 | Pyrimidine-2,4-dione targets STAT3 signaling pathway to induce cytotoxicity in hepatocellular carcinoma cells. |
| AID632968 | Antitumor activity against human MM1 cells after 24 to 72 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
ISSN: 1464-3391 | Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. |
| AID632966 | Antitumor activity against human OCI-My4 cells after 24 to 72 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
ISSN: 1464-3391 | Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. |
| AID1709759 | Cytotoxicity against human HeLa cells assessed as inhibition of cell viability measured after 48 hrs by MTT assay | 2021 | ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
ISSN: 1948-5875 | |
| AID1709758 | Inhibition of IL-6 induced STAT3 transcriptional activity in human HEK-Blue IL-6 cells assessed as secreted embryonic alkaline phosphatase reporter gene expression measured after 20 hrs by microplate reader | 2021 | ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
ISSN: 1948-5875 | |
| AID632964 | Antitumor activity against human U373MG cells after 24 to 72 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
ISSN: 1464-3391 | Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. |
| AID1709807 | Cytotoxicity against human HEK-Blue IL-6 cells assessed as cell death at > 10 uM | 2021 | ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
ISSN: 1948-5875 | |
| AID632970 | Ratio of AG490 IC50 to compound IC50 for human U373MG cells | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
ISSN: 1464-3391 | Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. |
| AID1064868 | Cytotoxicity against human 73M cells assessed as cell viability after 8 days by Alamar Blue assay | 2013 | ACS medicinal chemistry letters, Nov-14, Volume: 4, Issue:11
ISSN: 1948-5875 | Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma. |
| AID1709794 | Inhibition of IL-6 induced STAT3 transcriptional activity in human HEK-Blue IL-6 cells assessed as secreted embryonic alkaline phosphatase reporter gene expression by microplate reader | 2021 | ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
ISSN: 1948-5875 | |
| AID632965 | Antitumor activity against human U87MG cells after 24 to 72 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
ISSN: 1464-3391 | Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. |
| AID1709761 | Cytotoxicity against human HEK 293T cells assessed as cell growth inhibition at 10 uM measured after 48 hrs by MTT assay | 2021 | ACS medicinal chemistry letters, May-13, Volume: 12, Issue:5
ISSN: 1948-5875 | |
| AID632969 | Ratio of AG490 IC50 to compound IC50 for human U87MG cells | 2011 | Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
ISSN: 1464-3391 | Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. |
| AID1064870 | Cytotoxicity against human 30M cells assessed as cell viability after 8 days by Alamar Blue assay | 2013 | ACS medicinal chemistry letters, Nov-14, Volume: 4, Issue:11
ISSN: 1948-5875 | Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347414 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
Research
Studies (82)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (10.98) | 29.6817 |
| 2010's | 57 (69.51) | 24.3611 |
| 2020's | 16 (19.51) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (1.22%) | 5.53% |
| Reviews | 1 (1.22%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 80 (97.56%) | 84.16% |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Absence Seizure | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Absence Status | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Disease | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adenocarcinoma Of Kidney | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adenoma, Prostatic | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Aggression | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Airway Remodeling | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Allodynia | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Angiogenesis, Pathologic | 0 | | 2010 | 2015 | 10.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Anoxemia | 0 | | 2021 | 2023 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Apnea, Obstructive Sleep | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Arthritis, Degenerative | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Asthma | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Asthma, Bronchial | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Astrocytoma, Grade IV | 0 | | 2007 | 2019 | 11.0 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| B-Cell Chronic Lymphocytic Leukemia | 0 | | 2015 | 2019 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| B-Cell Lymphoma | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| B16 Melanoma | 0 | | 2008 | 2014 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Benign Neoplasms, Brain | 0 | | 2007 | 2020 | 10.6 | low | 0 | 0 | 0 | 4 | 11 | 0 |
| Bladder Cancer | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bone Cancer | 0 | | 2017 | 2019 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Bone Neoplasms | 0 | | 2017 | 2019 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Brain Neoplasms | 0 | | 2007 | 2020 | 10.6 | low | 0 | 0 | 0 | 4 | 11 | 0 |
| Breast Cancer | 0 | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Breast Neoplasms | 0 | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cancer of Cervix | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Esophagus | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Head | 0 | | 2009 | 2015 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Cancer of Kidney | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Liver | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cancer of Lung | 0 | | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cancer of Mouth | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cancer of Nose | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Ovary | 0 | | 2015 | 2017 | 8.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Cancer of Prostate | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Skin | 0 | | 2013 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Cancer of Stomach | 0 | | 2014 | 2021 | 6.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Cancer of the Tongue | 0 | | 2013 | 2014 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Carcinoma, Epidermoid | 0 | | 2009 | 2017 | 10.3 | low | 0 | 0 | 0 | 1 | 6 | 0 |
| Carcinoma, Hepatocellular | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Carcinoma, Non-Small Cell Lung | 0 | | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Carcinoma, Non-Small-Cell Lung | 0 | | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Carcinoma, Renal Cell | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carcinoma, Squamous Cell | 0 | | 2009 | 2017 | 10.3 | low | 0 | 0 | 0 | 1 | 6 | 0 |
| Cardiovascular Stroke | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Disease | 0 | | 2009 | 2014 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Chronic Illness | 0 | | 2009 | 2014 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Cirrhosis | 0 | | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Cognitive Decline | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cognitive Dysfunction | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Colitis, Granulomatous | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Constriction, Pathologic | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Constriction, Pathological | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Crohn Disease | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Di Guglielmo Disease | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Diabetic Retinopathy | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diffuse Lymphocytic Lymphoma, Poorly-Differentiated | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Disease Exacerbation | 0 | | 2013 | 2017 | 9.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Disease Models, Animal | 0 | | 2009 | 2020 | 9.0 | low | 0 | 0 | 0 | 2 | 9 | 0 |
| Endometrioma | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Endometriosis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ER-Negative PR-Negative HER2-Negative Breast Cancer | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Erythremia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Esophageal Neoplasms | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Esophageal Squamous Cell Carcinoma | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Experimental Neoplasms | 0 | | 2014 | 2020 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Experimental Radiation Injuries | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fibrosis | 0 | | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Fibrosis, Radiation | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Germinoblastoma | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Glial Cell Tumors | 0 | | 2007 | 2020 | 10.1 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| Glioblastoma | 0 | | 2007 | 2019 | 11.0 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| Glioma | 0 | | 2007 | 2020 | 10.1 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| Glioma, Subependymal | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Granulocytic Leukemia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Head and Neck Neoplasms | 0 | | 2009 | 2015 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Hepatocellular Carcinoma | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypertrophy | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypoxia | 0 | | 2021 | 2023 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Infantile Respiratory Distress Syndrome | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Inflammation | 0 | | 2009 | 2021 | 9.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Innate Inflammatory Response | 0 | | 2009 | 2021 | 9.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Invasiveness, Neoplasm | 0 | | 2015 | 2017 | 7.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Kahler Disease | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Kaposi Sarcoma | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Kidney Neoplasms | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leukemia, Erythroblastic, Acute | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 0 | | 2015 | 2019 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Leukemia, Myeloid | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Neoplasms | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Lung Neoplasms | 0 | | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Lymph Node Metastasis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphoma | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphoma, B-Cell | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphoma, Mantle-Cell | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphoma, T-Cell | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Malignant Melanoma | 0 | | 2009 | 2017 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Melanoma | 0 | | 2009 | 2017 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Metastase | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Mouth Neoplasms | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Multiple Myeloma | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple Neurofibromas | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Myocardial Infarction | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neointima | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neoplasm Metastasis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nerve Pain | 0 | | 2014 | 2020 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Neuralgia | 0 | | 2014 | 2020 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Neurilemmoma | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Neurilemoma | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Neurofibromatoses | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Obesity | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Osteoarthritis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Osteogenic Sarcoma | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Osteosarcoma | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ovarian Neoplasms | 0 | | 2015 | 2017 | 8.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Peritoneal Carcinomatosis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Peritoneal Neoplasms | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Polycythemia Vera | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Prostatic Hyperplasia | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Prostatic Neoplasms | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Radiation Pneumonitis | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Respiratory Distress Syndrome, Newborn | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sarcoma, Kaposi | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Scleroderma, Systemic | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Sclerosis, Systemic | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Seizures | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Skin Neoplasms | 0 | | 2013 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Sleep Apnea, Obstructive | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Status Epilepticus | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Stomach Neoplasms | 0 | | 2014 | 2021 | 6.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| T-Cell Lymphoma | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Tongue Neoplasms | 0 | | 2013 | 2014 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Triple Negative Breast Neoplasms | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Urinary Bladder Neoplasms | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Uterine Cervical Neoplasms | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
STAT3-Mediated Astrocyte Reactivity Associated with Brain Metastasis Contributes to Neurovascular Dysfunction.Cancer research, , 12-15, Volume: 80, Issue:24, 2020
Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.Clinical cancer research : an official journal of the American Association for Cancer Research, , 09-15, Volume: 26, Issue:18, 2020
TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway.Oncology reports, , Volume: 41, Issue:2, 2019
Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.PloS one, , Volume: 10, Issue:5, 2015
Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells.Oncotarget, , Apr-30, Volume: 6, Issue:12, 2015
Suppression of autophagy augments the radiosensitizing effects of STAT3 inhibition on human glioma cells.Experimental cell research, , Jan-15, Volume: 330, Issue:2, 2015
Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.The Journal of pharmacology and experimental therapeutics, , Volume: 349, Issue:3, 2014
Therapeutic targets in subependymoma.Journal of neuroimmunology, , Dec-15, Volume: 277, Issue:1-2, 2014
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.Neuro-oncology, , Volume: 15, Issue:2, 2013
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.International journal of cancer, , Jul-01, Volume: 131, Issue:1, 2012
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.Oncology reports, , Volume: 26, Issue:5, 2011
A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.Cancer immunology, immunotherapy : CII, , Volume: 58, Issue:7, 2009
The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.Clinical neurosurgery, , Volume: 56, 2009
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 14, Issue:18, 2008
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.Cancer research, , Oct-15, Volume: 67, Issue:20, 2007
Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.Oncogene, , Jan-10, Volume: 32, Issue:2, 2013
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.Biochemical pharmacology, , Jun-01, Volume: 81, Issue:11, 2011
Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity.Molecular carcinogenesis, , Volume: 56, Issue:10, 2017
Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma.Molecular cancer, , Dec-21, Volume: 14, 2015
STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo.Oncology reports, , Volume: 31, Issue:5, 2014
[Signal transducer and activator of transcription-3 inhibitor WP1066 affects human tongue squamous cell carcinoma proliferation and apoptosis in vitro and in vivo].Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, , Volume: 49, Issue:5, 2014
WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.Scientific reports, , Dec-17, Volume: 4, 2014
[Signal transducers and activators of transcription-3 modulates human squamous cell carcinoma invasion via targeting mircoRNA-21 in vitro].Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, , Volume: 48, Issue:9, 2013
Therapeutic suppression of constitutive and inducible JAK\\STAT activation in head and neck squamous cell carcinoma.Journal of experimental therapeutics & oncology, , Volume: 8, Issue:2, 2009
Blockade of IL-11 Trans-Signaling or JAK2/STAT3 Signaling Ameliorates the Profibrotic Effect of IL-11.Immunological investigations, , Volume: 52, Issue:6, 2023
Delayed Administration of WP1066, an STAT3 Inhibitor, Ameliorates Radiation-Induced Lung Injury in Mice.Lung, , Volume: 194, Issue:1, 2016
TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway.Oncology reports, , Volume: 41, Issue:2, 2019
Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.PloS one, , Volume: 10, Issue:5, 2015
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.Neuro-oncology, , Volume: 15, Issue:2, 2013
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.Oncology reports, , Volume: 26, Issue:5, 2011
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.Cancer research, , Oct-15, Volume: 67, Issue:20, 2007
Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.Clinical cancer research : an official journal of the American Association for Cancer Research, , 09-15, Volume: 26, Issue:18, 2020
WP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3.Cancer science, , Volume: 108, Issue:3, 2017
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.Neoplasia (New York, N.Y.), , Volume: 17, Issue:7, 2015
Suppression of autophagy augments the radiosensitizing effects of STAT3 inhibition on human glioma cells.Experimental cell research, , Jan-15, Volume: 330, Issue:2, 2015
Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.The Journal of pharmacology and experimental therapeutics, , Volume: 349, Issue:3, 2014
The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.Clinical neurosurgery, , Volume: 56, 2009
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.Oncogene, , Apr-12, Volume: 26, Issue:17, 2007
FOXM1 activates JAK1/STAT3 pathway in human osteoarthritis cartilage cell inflammatory reaction.Experimental biology and medicine (Maywood, N.J.), , Volume: 246, Issue:6, 2021
Leptin attenuates cardiac apoptosis after chronic ischaemic injury.Cardiovascular research, , Jul-15, Volume: 83, Issue:2, 2009
Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.Oncogene, , Jan-10, Volume: 32, Issue:2, 2013
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.Biochemical pharmacology, , Jun-01, Volume: 81, Issue:11, 2011
Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.Molecular and cellular biochemistry, , Volume: 436, Issue:1-2, 2017
Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.The Journal of investigative dermatology, , Volume: 133, Issue:8, 2013
A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.Cancer immunology, immunotherapy : CII, , Volume: 58, Issue:7, 2009
Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway.Cancer research and treatment, , Volume: 49, Issue:2, 2017
The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.International journal of oncology, , Volume: 48, Issue:6, 2016
Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.Genetics and molecular research : GMR, , Mar-30, Volume: 14, Issue:1, 2015
Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity.Molecular carcinogenesis, , Volume: 56, Issue:10, 2017
Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model.Cancer biology & therapy, , Volume: 15, Issue:9, 2014
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.Neuro-oncology, , Volume: 15, Issue:2, 2013
STAT3-Mediated Astrocyte Reactivity Associated with Brain Metastasis Contributes to Neurovascular Dysfunction.Cancer research, , 12-15, Volume: 80, Issue:24, 2020
Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.Clinical cancer research : an official journal of the American Association for Cancer Research, , 09-15, Volume: 26, Issue:18, 2020
TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway.Oncology reports, , Volume: 41, Issue:2, 2019
Suppression of autophagy augments the radiosensitizing effects of STAT3 inhibition on human glioma cells.Experimental cell research, , Jan-15, Volume: 330, Issue:2, 2015
Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.PloS one, , Volume: 10, Issue:5, 2015
Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells.Oncotarget, , Apr-30, Volume: 6, Issue:12, 2015
Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.The Journal of pharmacology and experimental therapeutics, , Volume: 349, Issue:3, 2014
Therapeutic targets in subependymoma.Journal of neuroimmunology, , Dec-15, Volume: 277, Issue:1-2, 2014
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.Neuro-oncology, , Volume: 15, Issue:2, 2013
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.International journal of cancer, , Jul-01, Volume: 131, Issue:1, 2012
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.Oncology reports, , Volume: 26, Issue:5, 2011
A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.Cancer immunology, immunotherapy : CII, , Volume: 58, Issue:7, 2009
The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.Clinical neurosurgery, , Volume: 56, 2009
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 14, Issue:18, 2008
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.Cancer research, , Oct-15, Volume: 67, Issue:20, 2007
Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.Oncogene, , Jan-10, Volume: 32, Issue:2, 2013
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.Biochemical pharmacology, , Jun-01, Volume: 81, Issue:11, 2011
Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity.Molecular carcinogenesis, , Volume: 56, Issue:10, 2017
Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma.Molecular cancer, , Dec-21, Volume: 14, 2015
STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo.Oncology reports, , Volume: 31, Issue:5, 2014
WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.Scientific reports, , Dec-17, Volume: 4, 2014
[Signal transducer and activator of transcription-3 inhibitor WP1066 affects human tongue squamous cell carcinoma proliferation and apoptosis in vitro and in vivo].Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, , Volume: 49, Issue:5, 2014
[Signal transducers and activators of transcription-3 modulates human squamous cell carcinoma invasion via targeting mircoRNA-21 in vitro].Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, , Volume: 48, Issue:9, 2013
Therapeutic suppression of constitutive and inducible JAK\\STAT activation in head and neck squamous cell carcinoma.Journal of experimental therapeutics & oncology, , Volume: 8, Issue:2, 2009
LncRNAs linc00311 and AK141205 are identified as new regulators in STAT3-mediated neuropathic pain in bCCI rats.European journal of pharmacology, , Feb-05, Volume: 868, 2020
Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.Clinical cancer research : an official journal of the American Association for Cancer Research, , 09-15, Volume: 26, Issue:18, 2020
Interaction between microglia and retinal pigment epithelial cells determines the integrity of outer blood-retinal barrier in diabetic retinopathy.Glia, , Volume: 67, Issue:2, 2019
Influence of mesenchymal stem cells on respiratory distress syndrome in newborn swines via the JAK-STAT signaling pathway.European review for medical and pharmacological sciences, , Volume: 23, Issue:17, 2019
STAT3 balances myocyte hypertrophy vis-à-vis autophagy in response to Angiotensin II by modulating the AMPKα/mTOR axis.PloS one, , Volume: 12, Issue:7, 2017
The effect of STAT3 inhibition on status epilepticus and subsequent spontaneous seizures in the pilocarpine model of acquired epilepsy.Neurobiology of disease, , Volume: 62, 2014
STAT3 inhibitor WP1066 as a novel therapeutic agent for bCCI neuropathic pain rats.Brain research, , Oct-02, Volume: 1583, 2014
Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation.Basic research in cardiology, , Volume: 107, Issue:3, 2012
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.International journal of cancer, , Jul-01, Volume: 131, Issue:1, 2012
The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.Clinical neurosurgery, , Volume: 56, 2009
Leptin attenuates cardiac apoptosis after chronic ischaemic injury.Cardiovascular research, , Jul-15, Volume: 83, Issue:2, 2009
Blockade of IL-11 Trans-Signaling or JAK2/STAT3 Signaling Ameliorates the Profibrotic Effect of IL-11.Immunological investigations, , Volume: 52, Issue:6, 2023
Delayed Administration of WP1066, an STAT3 Inhibitor, Ameliorates Radiation-Induced Lung Injury in Mice.Lung, , Volume: 194, Issue:1, 2016
TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway.Oncology reports, , Volume: 41, Issue:2, 2019
Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.PloS one, , Volume: 10, Issue:5, 2015
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.Neuro-oncology, , Volume: 15, Issue:2, 2013
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.Oncology reports, , Volume: 26, Issue:5, 2011
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.Cancer research, , Oct-15, Volume: 67, Issue:20, 2007
Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.Clinical cancer research : an official journal of the American Association for Cancer Research, , 09-15, Volume: 26, Issue:18, 2020
WP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3.Cancer science, , Volume: 108, Issue:3, 2017
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.Neoplasia (New York, N.Y.), , Volume: 17, Issue:7, 2015
Suppression of autophagy augments the radiosensitizing effects of STAT3 inhibition on human glioma cells.Experimental cell research, , Jan-15, Volume: 330, Issue:2, 2015
Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.The Journal of pharmacology and experimental therapeutics, , Volume: 349, Issue:3, 2014
The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.Clinical neurosurgery, , Volume: 56, 2009
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.Oncogene, , Apr-12, Volume: 26, Issue:17, 2007
FOXM1 activates JAK1/STAT3 pathway in human osteoarthritis cartilage cell inflammatory reaction.Experimental biology and medicine (Maywood, N.J.), , Volume: 246, Issue:6, 2021
Leptin attenuates cardiac apoptosis after chronic ischaemic injury.Cardiovascular research, , Jul-15, Volume: 83, Issue:2, 2009
Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.Oncogene, , Jan-10, Volume: 32, Issue:2, 2013
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.Biochemical pharmacology, , Jun-01, Volume: 81, Issue:11, 2011
Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.Molecular and cellular biochemistry, , Volume: 436, Issue:1-2, 2017
Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.The Journal of investigative dermatology, , Volume: 133, Issue:8, 2013
A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.Cancer immunology, immunotherapy : CII, , Volume: 58, Issue:7, 2009
Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.The Journal of pharmacology and experimental therapeutics, , Volume: 349, Issue:3, 2014
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.International journal of cancer, , Jul-01, Volume: 131, Issue:1, 2012
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 14, Issue:18, 2008
STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells.Oncology reports, , Volume: 38, Issue:4, 2017
Irisin reverses the IL-6 induced epithelial-mesenchymal transition in osteosarcoma cell migration and invasion through the STAT3/Snail signaling pathway.Oncology reports, , Volume: 38, Issue:5, 2017
Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.Genetics and molecular research : GMR, , Mar-30, Volume: 14, Issue:1, 2015
Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells.Oncotarget, , Apr-30, Volume: 6, Issue:12, 2015
Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.PloS one, , Volume: 10, Issue:5, 2015
Enhanced miR-210 expression promotes the pathogenesis of endometriosis through activation of signal transducer and activator of transcription 3.Human reproduction (Oxford, England), , Volume: 30, Issue:3, 2015
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.British journal of cancer, , May-25, Volume: 102, Issue:11, 2010
Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway.Cancer research and treatment, , Volume: 49, Issue:2, 2017
The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway.International journal of oncology, , Volume: 48, Issue:6, 2016
Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.Genetics and molecular research : GMR, , Mar-30, Volume: 14, Issue:1, 2015
Safety/Toxicity (1)
Dosage (1)